Early Versus Late Adjunctive Vasopressin in Septic Shock

Launched by THE CLEVELAND CLINIC · Nov 26, 2024

Keywords

ClinConnect Summary

The CASPER-Pilot study is a clinical trial aimed at understanding the best timing for giving a medication called vasopressin to patients experiencing septic shock, a serious condition where the body has a severe reaction to an infection. The researchers want to see if starting vasopressin early, compared to the usual timing, can help improve patient outcomes. They will use a special computer system to help decide when to start treatment based on how much norepinephrine (another medication used to support blood pressure) a patient is receiving. This study will also check how well the computer system works and compare the health results of patients in both groups.

To participate in this trial, you need to be at least 18 years old and diagnosed with septic shock while being treated in the Cleveland Clinic Main Campus Medical ICU. You should be on a continuous infusion of norepinephrine at a dose higher than 5 micrograms per minute. However, if you are receiving any other similar medications at the time of enrollment, you won't be eligible for this study. If you choose to participate, you will be randomly assigned to either the early or standard treatment group, and the research team will closely monitor your health during the trial. This study is not yet recruiting participants, but it represents an important step in improving care for patients with septic shock.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 Years
• • Diagnosis of Septic Shock
• • Admitted to Cleveland Clinic Main Campus Medical ICU
• • Receiving continuous infusion of norepinephrine at a dose \> 5 mcg/min at time of enrollment
• Exclusion Criteria:
• • Administration of any other vasoactive agent other than norepinephrine at time of enrollment
• • Initiation of vasopressin by provider outside of the context of study when NE \< 10 mcg/min (before BPA firing)